Development: AI Across the Development Pipeline - Why Animal Health May Be Better Positioned Than Human Pharma

Instead of asking whether animal health can learn from human pharma’s playbook, this session asks what structural advantages animal health has that could make AI deployment faster, cheaper, and more impactful.

Lower regulatory burden. Faster trial timelines. Lower cost of failure. Access to rich real-world data from PIMS and practice networks. A more concentrated market with fewer stakeholders. These are genuine structural advantages, and they’re being exploited by companies across the value chain, from target identification to manufacturing optimisation.